New Pfizer COVID-19 pill reduces hospital, death risk by 90%, company says
Global News
Pfizer's pill to treat COVID-19 reduces the risk of hospitalization and death by nearly 90 per cent, the company said Friday when it released preliminary results.
Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90 per cent as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.
Currently all COVID-19 treatments used in the U.S. require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.
Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.
Researchers worldwide have been racing to find a pill against COVID-19 that can be taken at home to ease symptoms, speed recovery and reduce the crushing burden on hospitals and doctors.
Pfizer released preliminary results Friday of its study of 775 adults. Patients taking the company’s drug along with another antiviral had an 89 per cent reduction in their combined rate of hospitalization or death after a month, compared to patients taking a dummy pill. Fewer than one per cent of patients taking the drug needed to be hospitalized and no one died. In the comparison group, seven per cent were hospitalized and there were seven deaths.
“We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90 per cent efficacy and 100 per cent protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer, in an interview.
Study participants were unvaccinated, with mild-to-moderate COVID-19, and were considered high risk for hospitalization due to health problems like obesity, diabetes or heart disease. Treatment began within three to five days of initial symptoms, and lasted for five days.
Pfizer reported few details on side effects but said rates of problems were similar between the groups at about 20 per cent.
The deadly haze covered monuments and high-rise buildings in the capital of New Delhi, with visibility so low that airlines warned of delays.
The death is being investigated by federal authorities but "the preliminary cause" has been ruled an accident.
The incident took place more than a month ago, on October 13, but it wasn't reported until the British tabloids got wind of the story.
Health officials said Saturday they have confirmed the first U.S. case of a new form of mpox that was first seen in eastern Congo.
Washington is easing limits on what Ukraine can strike with U.S.-made weaponry, U.S. officials told The Associated Press on Sunday.
Ukraine plans to conduct its first long-range attacks in the coming days, sources said, without revealing details due to operational security concerns.
Concerns storm surges could raise water levels between one and three feet above ground level as Tropical Storm Sara makes landfall in Belize.
Air defenses could be heard engaging drones over Kyiv in the night, and a series of powerful blasts rang out across the city as the missile attack was under way in the morning.
John Kirton, head of the G20 Research Group, says the forum is the main tool countries have to prepare for the second Donald Trump presidency.
Israeli airstrikes on the village of Khreibeh in the Baalbek District of eastern Lebanon killed six people on Saturday, including three children the Lebanese health ministry said.
The APEC summit marked the end of trade talks that should lead to Canada signing a new deal with the world's fourth-most populous country next year.